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Abstract A model of the tertiary structure of human IL-6, de- 
rived from the crystal-structure of granulocyte-colony stimulat- 
ing factor, reveals a 5th helical region in the loop between the first 
and second ~-helix. To investigate the importance of this region 
for biological activity of IL-6, residues Glu-52, Ser-53, Ser-54, 
Lys-55, Glu-56, Leu-58 and Glu-60 were individually replaced by 
alanine. IL-6.Leu-58Ala displayed a 5-fold reduced biological 
activity on the IL-6-responsive human cell lines XG-1 and A375. 
This reduction in bioactivity was shown to be due to a decreased 
capacity of the mutant protein to trigger IL-6 receptor-c~-chain- 
dependent binding to the IL-6 signal transducer, gpl30. 
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1. Introduction 
Interleukin-6 (IL-6) is a multifunctional cytokine with a cen- 
tral role in host defense mechanisms [1]. The biological func- 
tions of IL-6 result from binding to a specific low-affinity IL-6 
receptor (IL-6Rc0 [2]. The IL-6/IL-6Rc~ complex induces di- 
sulphide-linked homodimerization a d tyrosine phosphoryla- 
tion of a signal transducing receptor component, gp130 [3,4]. 
Both 1L-6 and IL-6Rc~ cannot independently bind to gpl30 [5]. 
Gpl30 is not specific for 1L-6, but is also part of the receptor 
complexes of leukemia inhibitory factor, oncostatin M, ciliary 
neurotrophic factor, IL-11 and probably also of the recently 
described novel cytokine cardiotrophin-1 [5,6]. In a variety of 
human diseases uncontrolled expression of IL-6 is observed 
and thought o play a role in the pathogenesis of these diseases 
(for review see [1]). Reagents which can block IL-6 activity such 
as IL-6 receptor antagonists may therefore have therapeutic 
value. For a rational design of such molecules detailed knowl- 
edge of the structure function relationships of human (h) IL-6 
is required. 
IL-6 is a member of the long-chain family of cytokines [7,8] 
with a similar anti-parallel four c~-helical bundle topology as 
growth hormone, granulocyte-colony stimulating factor (G- 
CSF) and leukemia inhibitory factor, the crystal structures of 
which have been determined [9 11]. Based on the structure of 
G-CSF, which is most homologous in primary structure to 
1L-6. a three-dimensional model of IL-6 has been built by using 
*Corresponding author. Fax: (31) (20) 512-3170. 
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molecular modelling techniques [12]. In this model IL-6 con- 
tains a core of 4 ~-helices (A,B,C,D) which are connected by 
long loops in an up-up-down-down topology. In addition to 
helices A-D, G-CSF contains a small helical region in the A-B 
loop consisting of a so-called '3~0-helix' of tour residues and a 
six-residue ~-helix (Fig. 1A) [10]. In G-CSF this region is rela- 
tively exposed and protrudes from the main body of the struc- 
ture [10]. Interestingly, this helical region may be important for 
the biological activity of G-CSF because it overlaps with epi- 
topes recognized by G-CSF specific neutralizing monoclonal 
antibodies (mAb) [13]. 
Based on the G-CSF structure, a fifth helical region in the 
IL-6 A-B loop was predicted to run from residues Glu-52 or 
Ser-53 Leu-65 (Fig. I B) [12]. Previous experiments suggest thai 
this helical region of IL-6 may be important for the interaction 
of the IL-6/IL-6R~ complex with gpl30: in the three-dimen- 
sional model it is in close proximity to the start of helix D, 
which has been identified to be important for the IL-6R~- 
dependent gp 130 interaction (site I or fl 1 -region) [14,15]. More 
importantly, human/mouse chimeric proteins of IL-6 in which 
residues Lys-42 Ala-57 (the 2A or fl2-region, [12,15]), or Cys-51 
Glu-56 ([16], Fig. lB) of hlL-6 were replaced with the corre- 
sponding residues of mouse IL-6 showed a strongly reduced 
capacity to trigger the binding of the IL-6/IL-6R:~ complex to 
gpl30. To identify single residues in IL-6 important fi}r the 
IL-6R~-dependent binding to gp130, we have constructed alan- 
ine substitution mutants of residues Glu-52 Glu-60 of hlL-6 
(indicated in Fig. 1A) and analyzed their bioactivity and recep- 
tor binding characteristics. 
2. Materials and methods 
2. l. Reagents 
Recombinant wild type (wt) hIL-6 {Ala-1 Met-185) was purified 
from E. coli BL21 (DE3) (a kind gift from Dr. G. Pruyn, Nijmegen, The 
Netherlands) carrying the pET8c-hlL-6 cDNA expression vector as 
described [14]. 
2.2. Construction o['expression p&smM, sand expression and purification 
~/ IL-6 mutant proteins 
Site-directed mutagenesis onthe hlL-6 cDNA was done by a two- 
step PCR mutagenesis technique as described before [15,17]. To facili- 
tate subcloning of PCR fragments, we introduced a unique EcoRI site 
into the IL-6 coding region by introducing two silent substitutions in 
the codons of Glu-94 and Phe-95 (GAGTTT--~GAATTC). We then 
used the unique EcoNI and EcoRl sites tk~r subcloning of PCR frag- 
ments with alanine substitutions of Glu-52, Ser-53, Scr-54, Lys-55, 
Glu-56, Leu-58 and Glu-60, in the T7 promotor-vector pRSET6D (a 
kind gilt from Dr. T. Stoyan, Aachen, Germany). If possible, restriction 
sites were concomitantly introduced, with the alanine substitutions, to 
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facilitate identification of positive clones. Primers were synthesized on 
an Applied Biosystems DNA synthesizer type 381A (Warrington, UK). 
Mutagenesis primers (antisense) used were Glu-52Ala; 5'-CTT TGC 
TGC TTG CAC ACA TGT T-3', Ser-53Ala (HindIII); 5'-GTG CCT 
CTT TGG AAG CTT CAC ACA TGT TA-3', Ser-54Ala (Eco47III); 
5'-GTG CCT CTT TAG CGC TTT CAC AC-3', Lys-55Ala (HaeII); 
5'-CCA GTG CCT CAG CGC TGC TTT CAC-3', Glu-56Ala 
(HaeIII); 5'-CTG CCA GTG CGG CCT TGC TGC TTT C-3', Leu- 
58Ala (PvuII); 5'-GTT GTT TTC TGC AGC TGC CTC TTT GC-3', 
and Glu-60Ala (HaeIII); 5'-GTT CAG GTT GTT GGC CGC CAG 
TGC CTC-3'. The IL-6.Arg-31Ala plasmid (kindly provided by Dr. R. 
Kastelein, DNAX Research Institute, Palo Alto, CA, USA) was con- 
structed by the method of Kunkel et al. as described [18]. The integrity 
of the constructs was verified by restriction enzyme digestion and nucle- 
otide sequence analysis on dsDNA of the EcoNI-EcoRI fragments with 
the dideoxy chain termination method by using the Sequenase kit (Bio- 
chemical Corp., Cleveland, USA). For expression of the IL-6 mutant 
proteins, the vectors were transformed into E. coli BL21 (DE3) and the 
proteins were purified from inclusion bodies and quantitated as de- 
scribed [14]. IL-6 bioassays The capacity of IL-6 and IL-6 mutant 
proteins to induce the proliferation of B9 mouse hybridoma cells and 
XG-1 human myeloma cells ([19]; kindly provided by Dr. B. Klein, 
Institute for Molecular Genetics, Montpellier, France), was measured 
as described elsewhere [14,15]. IL-6 can inhibit the proliferation of the 
human melanoma cell line A375 [20]. A375 cells (kindly provided by 
Dr. C. Figdor, NKI, Amsterdam, The Netherlands) were maintained 
in Iscove's modified Dulbecco's medium supplemented with 5% (v/v) 
fetal calf serum, 5 x 10 -5 M 2-mercapto-ethanol, 100 IU penicillin, 100 
/.tg/ml streptomycin, 20/2g/ml human transferrin (Behringwerke, Mar- 
burg, Germany). To test the ability of IL-6 mutant proteins to inhibit 
proliferation of A375 cells, the cells were incubated in 96-well flat- 
bottomed microtiter plates (4 x 103 cells/well) in triplicate for 72 h in 
the presence of serial dilutions of the samples to be tested. After this 
culture period, the cells were pulse-labeled with 7.4 kBq of [3H]thymid- 
ine (74 Gbq/mmol) for 5 h, detached with 10 mM EDTA and the 
radioactivity incorporated in the nuclei was measured as described [14]. 
2.3. Receptor binding experiments 
To investigate he binding of IL-6 mutant proteins to IL-6R~, a solid 
phase assay was used in which the capacity of the IL-6 mutant proteins 
was measured to compete for binding of biotinylated IL-6 to immobi- 
lized soluble (s) IL-6R~ as described [15,21]. To measure gpl30 interac- 
tion, the capacity of IL-6 and the IL-6 mutant proteins to induce 
binding of a sgpl30-IgG1 fusion protein to immobilized sIL-6Rc~ was 
measured as described [21]. 
2.4. MAb binding experiments 
To study the structural integrity of the IL-6 mutant proteins their 
reactivity with conformation specific mAb was measured in sandwich 
ELISA's with mAb CLB.IL-6/8, mAb CLB.IL-6/15 or mAb CLB.IL- 
6/16 as coating antibodies and affinity purified biotinylated sheep 
polyclonal anti-IL-6 as detecting antibody as described before [22]. 
3. Results 
3.1. IL-6.Leu-58Ala has a reduced activity on IL-6 responsive 
human cells 
A panel of IL-6 variants was constructed in which residues 
Glu-52, Ser-53, Ser-54, Lys-55, Glu-56, Leu-58 and Glu-60 
were individually replaced by alanine. The biological activity 
of the mutant proteins was measured in three different bioas- 
says for IL-6: induction of proliferation of mouse B9 hybrid- 
oma cells and of human XG-1 myeloma cells, and inhibition of 
proliferation of the human melanoma cell line A375. In general 
the observed ifferences in bioactivity between the mutant pro- 
teins were small. All mutant proteins had a similar activity as 
wtIL-6 in the mouse B9 assay with a maximum two-fold de- 
crease observed for the Ser-53Ala protein (Table 1). In the 
bioassays with human cells only the Leu-58Ala mutant protein 
displayed a consistent 5-fold reduction in specific activity in 
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Fig. 1. (A) Part of the alignment of the hIL-6 and hG-CSF primary 
sequence. Identical residues are indicated by asterisks. The alignment 
was obtained from ref. [12]. The location of the '3~0'- and o-helix and 
the disulfide bond of G-CSF are indicated [10]. The amino acids of I L-6 
that have been substituted to alanine in this study are indicated by an 
arrow. (B) Part of the alignment of the primary sequence of human and 
mouse (m) IL-6. Identical residues are indicated by asterisks. The align- 
ment was obtained from [12]. The location of the putative helical region, 
the disulphide bond, and L58 are indicated. The amino acids which 
have recently been identified to be important for gp130 interaction, by 
studying mouse/human chimeric molecules of IL-6 are also indicated 
by the box [16]. 
both assays (Table 1). The activities of the other mutant pro- 
teins varied less than three-fold from that of wtIL-6, whereas 
they all were more active on XG-1 cells then on A375 cells. The 
experimental error inherent o these measurements is approxi- 
mately a factor two (data not shown). Additional experiments 
would therefore be required to firmly establish these small 
differences. As suggested by the full activity of the Leu-58Ala 
mutant protein on B9 cells, the reduced activity on the human 
cells was probably not due to a perturbation of the overall 
tertiary structure of the Leu-58Ala protein. Also, the Leu- 
58Ala mutant protein bound with comparable affinity as wtIL- 
6 and the other mutant proteins to conformation specific mAbs 
8, 15 and 16 (Table 1). These results suggested therefore that 
the reduced bioactivity of the Leu58Ala protein is due to a 
defect in receptor binding. 
3.2. Leu-58 is involved in IL6Rot-dependent binding to gpl30 
We next studied the receptor binding characteristics of the 
IL-6 mutant proteins in binding assays with the soluble ex- 
tracellular domains of both IL-6R~ and gpl30. All mutant 
proteins bound with comparable affinity to sIL-6R~ as wtIL-6, 
with an observed maximum difference of a factor two (Glu- 
52Ala; Table 1). However, whereas the other mutant proteins 
had similar sgpl30 binding characteristics as wtIL-6, the Leu- 
58Ala protein showed a reduction in the sIL6Rc~-dependent 
binding to sgp130 (Table 1). To further substantiate this obser- 
vation and to rule out the possibility that this reduction in 
sgpl30 binding was in fact due to an indirect effect via sIL6R~, 
the receptor binding characteristics of the Leu-58Ala protein 
were compared with those of an IL-6 mutant protein, IL- 
6"Arg-31Ala, with a reduced affinity for IL6Rc~ (J.P.J. 
Brakenhoff and R. Kastelein, unpublished results). Both 
sIL6R~- and sgpl30-binding were measured. Again the Leu- 
58Ala protein showed a similar affinity for IL6Rc~ as wtIL-6, 
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Fig. 2. Interaction of IL-6.Arg-3 IAla and IL-6. Leu-58Ala with sIL- 
6Rce and sgp 130. (A) Competitive inhibition of the binding of biotinyl- 
ated IL-6 to slL-6Rc~ by increasing concentrations of wtIL-6, Arg- 
31Ala and Leu-58Ala. (B) sgpl30-1gG1 fusion protein was incubated 
with increasing concentrations of IL-6 (or IL-6-variants) and immobi- 
lized sIL-6Rcc Both assays were done on the same day with the same 
dilution series of each protein. The average values of duplicate measure- 
ments are shown of one experiment out of two. 
whereas that of the Arg31Ala protein was -6-fo ld reduced (Fig. 
2A). In contrast, whereas the dose-response curve of the Arg- 
31Ala protein reached a similar maximum response as that of 
wtIL-6, indicating a similar capacity to bind to sgp 130 as wtlL- 
6, again the maximum response of the Leu-58Ala protein was 
reduced. Interestingly, the dose response curves of IL-6" Leu- 
58Ala and IL-6.Arg-31Ala were shifted to the right, compared 
to that of wtIL-6. For IL-6.Arg-31Ala the extent of the shift 
corresponds to the reduced affinity for sIL6R~. For IL-6. Leu- 
58Ala this shift must be due to the reduced affinity for sgpl30. 
4. D iscuss ion  
In previous studies three regions of hIL-6 have been shown 
to be important for the IL6Rc~-dependent interaction with 
gpl30, which we recently designated f l l - f l3 [21]. The fl l region 
corresponds to [L-6 residues Gln-153 His-165 [14,15], the f12 
region to residues Lys-42-Ala-57 [12] and the f13 region to 
residues Tyr-32 and Gly-36 [23], Ser-119 and Val-122 ([24]; by 
using our numbering). It is unclear what the exact roles of the 
fl-regions are in IL-6-receptor activation. The active IL-6 recep- 
tor complex is thought o consist of two molecules of each IL-6, 
1L-6R~ and gpl30 [25,26]. Our current working hypothesis is 
that mutations in the fl-regions may either affect dimerization 
of IL-6, which may be necessary for gpl30 dimerization to 
occur, or a direct association with gpl30. (See [21] for a more 
extensive discussion on this topic.) 
To map the 'functional epitopes" [27] of Ig-6 that are in- 
volved in the Ig6Rc~-dependent i eraction with gpl30 in more 
detail, we have now performed alanine scanning mutagenesis 
[28] of residues close to or part of the f12 region. Only alanine 
substitution of residue Leu58, but not of residues Glu-52, Ser- 
53, Ser-54, Lys-55, Glu-56 or Glu-60 of 1L-6 significantly re- 
duced the binding of the ]L-6/sIL-6R~ complex to sgpl30 
(Table 1, Fig. 2B). In the tertiary structure model of Ig-6, 
Leu-58 is a solvent exposed residue in the central portion of the 
putative 5th helical region and could therefore very well be 
involved in a direct hydrophobic interaction with gp130 (Fig. 
3). After all, in the human growth hormone-growth hormone 
binding protein complex, hydrophobic interactions were found 
to contribute most to the binding free energy of the hormone 
receptor interaction [29]. 
The finding in this study that alanine substitutions of Glu- 
52 Glu-56 of Ik-6 did not affect gp130 binding, contrasted the 
observations by Ehlers et al. who showed the/32 region and in 
particular esidues Glu-52.Glu-56 thereof, to be important for 
gpl30 interaction [12,16]. By studying human/mouse chimeric 
proteins of IE-6, they showed that simultaneous replacement 
of residues Glu-52-Glu-56 of hIL-6 with the corresponding 
mouse residues resulted in an -30-fold reduction in bioactivity 
and I L-6R~-dependent gp130 binding [16]. Assuming that we 
indeed deal with a gp130 contact site, the identification of such 
a region by this approach was in fact an unexpected observa- 
tion because both mouse Ik-6 in complex with the mouse ~- 
chain and human IL-6 in complex with either the human or 
mouse ~-chain, are capable of triggering signal transduction via 
human gp130 [30]. This would imply that homologous residues 
Table I 
Characteristics of IL-6 mutant proteins with alanine substitutions of residues Glu-52 -Glu-60 ~' 
Bioassay b Receptor binding ~ mAb binding ~ 
B9 XG-1 A375 1L-6R:z gpl30 8 15 16 
wtIL-6 100 100 100 100 100 100 100 100 
E52A 97 167 42 44 105 44 58 56 
$53A 54 194 30 78 I10 40 54 59 
$54A 122 173 70 59 115 33 41 57 
K55A 125 145 43 40 115 58 49 57 
E56A 152 196 82 75 120 76 88 82 
L58A 93 20 18 94 d 16 ~ 31 60 75 
E60A 108 75 30 93 110 47 51 61 
"Mutant phenotype is indicated in single letter code. Responses of the mutant proteins in the various assays are expressed as a percentage of that 
of wtIL-6 (set at 100%) and are derived from ECs0 values (the effective concentration giving a half-maximal response). 
bBiological activity of IL-6 mutant proteins in the B9, XG-I and A375 assays was measured as described in section 2. Values represent averages of 
2 experiments. The average ECs0 in the B9 assay was 1 pg/ml, in the XG-1 assay 20 pg/ml and in the A375 assay 0.2 ng/ml, respectively. 
c Binding of IL-6 mutant proteins to slL-6R~t, sgpl30 and the IL-6 specific mAbs 8, 15 and 16 was measured as described in section 2. Values are 
the average of 2 experiments, except for gpl30 binding assay, where they represent the averages from duplicate measurements of one experiment. 
The average ECs0 of wtIL-6 in the IL-6Rc~ binding assay was 100 ng/ml, in the gpl30 binding assay 10 ng/ml, and in the mAb 8, 15 and 16 ELISA's 
2, 2, and 0.5 ng/ml, respectively. 
d Average of four assays. 
" ECs,~ could not be determined precisely, as no maximal response was obtained. (See also Fig. 2.) 
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Fig. 3. Three-dimensional model of IL-6. Top view of a ribbon repre- 
sentation of the hIL-6 model. The four long-chain helices are numbered 
A-D. Leu-58 in the putative fifth helical region of IL-6 is highlighted. 
between mouse and human IL-6 are involved. Introduction of 
non-homologous mouse residues in a human background 
would therefore be expected not to affect human gpl30 activa- 
tion. Viewed in this way, the observation that single substitu- 
tion of the non-conserved residues Glu-52-Glu-56 (Fig. 1B) 
with alanine residues resulted only in minor effects in the vari- 
ous assays, is not unexpected. Also, the involvement of Leu-58, 
which is conserved between human and mouse IL-6 (Fig. 1B), 
in the IL-6Ra-dependent gp130 interaction, is in line with this. 
How then to explain the large effect of simultaneous Glu-52 
Glu-56 substitution? One possibility could be that the charge 
reversal due to the Lys-55Asp substitution generates a repulsive 
force (see Fig. 1B). Otherwise, perturbation of the local tertiary 
structure of IL-6 due to the substitutions may affect the gp130 
interaction capability of other residues. 
Another puzzling observation is that the Leu-58Ala substitu- 
tion does not seem to affect IL-6 activity on mouse B9 cells 
(Table 1). More in general, substitutions in human IL-6 that 
disrupt human gpl30 binding, and bioactivity on human cells, 
have no or limited effects on mouse B9 cells [12,14,15]. These 
results suggest hat residues in human IL-6 that interact with 
human gpl30, may differ from the residues that interact with 
mouse gpl30. More experiments are required to resolve these 
issues. 
In conclusion, single alanine substitution of amino acid resi- 
dues Glu-52-Glu-60 of hIL-6 revealed that Leu-58, a solvent 
exposed residue in the tertiary structure model of hIL-6, is 
involved in IL-6R0~-dependent binding to gpl30. This might 
indicate that the putative fifth helix in IL-6 is involved in an 
interaction with gpl30. Because of the small effect of Leu-58 
substitution, it seems likely that besides Leu-58, other residues 
are involved. Further mutagenesis of this region is therefore 
required to identify additional residues involved in this interac- 
tion. Identification of single residues of IL-6 that are important 
for receptor interaction is a prerequisite for the rational design 
of small inhibitors of the molecule. Leu-58 is located just be- 
sides the IL-6 fl2-region [12]. It will be interesting to combine 
the Leu-58Ala mutation with il l-substitutions [14,15] and to 
test wether this protein is inactive on myeloma cells and antag- 
onizes IL-6 activity on these cells. 
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